TherageniX, have been awarded a £995,000 grant from Innovate UK. The funding will support the development of the Company’s gene therapy in a powder, a non-viral gene delivery system to improve tissue regeneration following surgery.

Optibrium, announced the acquisition of BioPharmics LLC, expanding its 3D drug design and modelling offering. Bringing decades of experience in computational chemistry and biology.

Polyplus (now part of Satorius), is announcing the pre-order availability of FectoVIR®-LV transfection reagent for lentiviral vector (LV) production.

The National Institutes of Health selected Exothera S.A. therapeutics to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2.

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), announced the signing of a strategic partnership with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.

Waters enables automated, high efficiency, and reproducible protein digestion with meaningful sample prep savings.

TVM Capital Life Science, together with specialty pharma company, Tillotts Pharma has announced that the companies will jointly invest up to USD 28 million in the newly formed U.S.-based biotechnology company, Mage Biologics Inc.

Cytiva has launched the NanoAssemblr commercial formulation system, purpose-built for clinical and commercial manufacturing of lipid nanoparticle medicines.

Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy.

Meissa Vaccines announced it has entered into a manufacturing agreement with Exothera S.A. delivering customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids.